

References

1. Wesnes K. The Cognitive Drug Research computerised assessment system: Application to clinical trials. 2003.
- 2-4. Walker MP, et al. [Series of papers on quantifying fluctuation in dementia]. Various journals. 2000.
5. Ballard CG, et al. Fluctuations in attention: PD dementia vs. DLB with Parkinsonism. *Neurology*. 2002;59:1714-1720.
6. Nicholl CG, et al. The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? *Int J Geriatr Psychiatry*. 1995;10:199-206.
7. McIntyre RS, Daniel DG, Vieta E, et al. The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia. *CNS Spectr*. 2023;28(3):319-330. doi:10.1017/S109285292200013X
8. Goetghebeur PJD, Micaletto M, Wesnes KA. Computerized Assessment of Attentional Processes and Drug Efficacy in Parkinson's Disease Dementia Using the CDR System. Paper presented at: AAT-AD/PD™ Focus Meeting 2018; March 15-18, 2018; Turin, Italy.
9. Goetghebeur PJD, Wesnes KA, Targum SD. D-Cycloserine Improves Difficult Discriminations in a Pattern Separation Task in Alzheimer's Disease Patients with Dementia. *J Alzheimers Dis*. 2019;69(2):377-383. doi:10.3233/JAD-181094
10. Wesnes KA, Simpson PM. The construct validity of the cognitive drug research computerised assessment system. 1994.
11. McKeith I, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. *Lancet*. 2000;356:2031-2036.
12. Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. *Int J Geriatr Psychiatry*. 2015;30(1):46-54.
13. Black K, et al. A computerised cognitive assessment of Multiple Sclerosis. *Proc Br Psychol Soc*. 1999;7:119.

14. Russell-Blacker CV, Greenwood DT, Wesnes KA, et al. Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. JAMA. 2004;292:1195-1204.
15. Wesnes KA, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study. 2001.
16. Wesnes KA, Edgar CJ. The role of human cognitive neuroscience in drug discovery for the dementias. Curr Opin Pharmacol. 2014;14:62-73.
17. Burton EJ, et al. White matter hyperintensities are associated with impairment of memory, attention and global cognitive performance in older stroke patients. Stroke. 2004;35:1270-1275.
18. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-2518.